Does lithium protect against dementia?

Bipolar Disorders

Volumn 12, Issue 1, 2010, Pages 87-94

  Kessing, Lars Vedel ^a   Forman, Julie Lyng ^b   Andersen, Per Kragh ^b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alzheimer's disease; Anticonvulsants; Antidepressants; Antipsychotics; Bipolar disorder; Dementia; Lithium

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM SALT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; BIPOLAR MANIA; CONTROLLED STUDY; DEMENTIA; DENMARK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; PRIORITY JOURNAL; PROTECTION; RISK REDUCTION;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEMENTIA; DENMARK; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LITHIUM CHLORIDE; MALE; MIDDLE AGED; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 75249102415     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00788.x     Document Type: Article

References (37)

1. Kessing LV, Olsen EW, Mortensen PB, Andersen PK. Dementia in affective disorder: a case-register study. Acta Psychiatr Scand 1999, 100:176-185.
2. Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 2003, 73:261-269.
3. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004, 75:1662-1666.
4. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000, 48:740-754.
5. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007, 170:1669-1675.
6. Fountoulakis KN, Vieta E, Bouras C. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol 2008, 11:269-287.
7. Mendes CT, Mury FB, de Sa ME. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci 2009, 259:16-22.
8. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008, 65:1331-1335.
9. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005, 19:20-22.
10. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007, 190:359-360.
11. Malig C. The civil registration system in Denmark 1996, Technical paper No 66, Bethesda MD, International Institute for Vital Registration and Statistics
12. Medicinal Product Statistics http://www.laegemiddelstyrelsen.dk, Accessed January 11, 2010
13. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999, 46:354-357.
14. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46:263-268.
15. Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull 1997, 44:82-84.
16. Klassifikation af sygdomme. Systematisk del. International Statistical Classification of Diseases and Health Related Problems 1993, Tenth revision (Danish Edition, Copenhagen, Munksgaard
17. Clayton D, Hills M. Statistical Models in Epidemiology 1993, Oxford, Oxford University Press
18. Kessing LV, Sondergård L, Forman JL, Andersen PK. Antidepressants and dementia. J Affect Disord 2009, 117:24-29.
19. Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005, 62:860-866.
20. Kessing LV. Cognitive impairment in the euthymic phase of affective disorder. Psychol Med 1998, 28:1027-1038.
21. Gattaz WF, Forlenza OV, Nunes PV. Lithium for prevention of Alzheimer's disease. Br J Psychiatry 2007, 190:359-360. Authors' reply
22. Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG. Enduring increased risk of developing depression and mania in patients with dementia. J Neurol Neurosurg Psychiatry 2002, 73:40-44.
23. Phung TK, Andersen BB, Hogh P, Kessing LV, Mortensen PB, Waldemar G. Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord 2007, 24:220-228.
24. Licht RW, Vestergaard P, Kessing LV, Larsen JK, Thomsen PH. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand 2003, 419:1-22.
25. Collins NS, Shapiro RA, Ramsay RE. Elders with epilepsy. Med Clin North Am 2006, 90:945-966.
26. Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S. Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev 2002, 54:1567-1577.
27. Rekling JC. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 2003, 335:167-170.
28. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK, Menji HK. Lithium-induced increase in human brain grey matter. Lancet 2000, 356:1241-1242.
29. Sassi RB, Nicoletti M, Brambilla P. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002, 329:243-245.
30. Moore GJ, Cortese BM, Glitz DA. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J Clin Psychiatry 2009, 70:699-705.
31. Moore GJ, Bebchuk JM, Hasanat K. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000, 48:1-8.
32. Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL. " Double depression": two-year follow-up. Am J Psychiatry 1983, 140:689-694.
33. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001, 48:17-28.
34. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006, 81:1-15.
35. Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997, 30:35-42.
36. Velligan DI, Newcomer J, Pultz J. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002, 53:239-248.
37. O'Grada C, Dinan T. Executive function in schizophrenia: what impact do antipsychotics have? Hum Psychopharmacol 2007, 22:397-406.